GIP (Glucose-dependent Insulinotropic Polypeptide)
GIP is a 42-aa incretin secreted by duodenal K-cells that potentiates insulin secretion in a glucose-dependent manner. Tirzepatide's superiority over semaglutide is attributed to its additional GIPR co-agonism.
Community Rating
No ratings yet
Compound Profile
GIP (Glucose-dependent Insulinotropic Polypeptide)
Key Data
Research reference only
Research Focus
Preclinical data
⚠ Research & Educational Use Only. GIP (Glucose-dependent Insulinotropic Polypeptide) is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Potentiates glucose-dependent insulin secretion from pancreatic beta cells — a foundational incretin effect
- Activates GIPR in adipocytes to promote fatty acid storage and triglyceride uptake — remodels fat distribution
- Tirzepatide's dual GLP-1R/GIPR agonism achieves greater weight loss than GLP-1R agonism alone (SURPASS trials)
- GIP (Glucose-dependent Insulinotropic Polypeptide) is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Potentiates glucose-dependent insulin secretion from pancreatic beta cells — a foundational incretin effect
- Activates GIPR in adipocytes to promote fatty acid storage and triglyceride uptake — remodels fat distribution
- Tirzepatide's dual GLP-1R/GIPR agonism achieves greater weight loss than GLP-1R agonism alone (SURPASS trials)
- Has direct bone anabolic effects via GIPR on osteoblasts — reduces fracture risk in clinical data
In Plain English
Simple summaryGIP (glucose-dependent insulinotropic polypeptide) is the other major incretin hormone alongside GLP-1 -- both are released after eating, both stimulate insulin secretion in a glucose-dependent way. GIP is released from K-cells in the upper small intestine within minutes of eating fat and carbohydrates. For decades after its discovery, GIP was the forgotten incretin: in Type 2 diabetes, the normal GIP insulin-stimulating response is lost (while GLP-1 response is relatively preserved), and early GIP receptor agonist research showed disappointing results. Everything changed when Eli Lilly's tirzepatide -- a GIP/GLP-1 dual agonist -- produced 22% average weight loss in the SURMOUNT trials, dramatically outperforming GLP-1 monotherapy. The GIP receptor's role in adipose tissue fat storage and energy partitioning turned out to be the key.
- Potentiates glucose-dependent insulin secretion from pancreatic beta cells — a foundational incretin effect
- Activates GIPR in adipocytes to promote fatty acid storage and triglyceride uptake — remodels fat distribution
- Tirzepatide's dual GLP-1R/GIPR agonism achieves greater weight loss than GLP-1R agonism alone (SURPASS trials)
The full scientific detail, mechanisms, citations, and dosing data, follows below.
What is GIP (Glucose-dependent Insulinotropic Polypeptide)?
Tap any underlined term for an instant definition.
GIP (Glucose-dependent Insulinotropic Polypeptide, also called gastric inhibitory polypeptide) is a 42-amino acid incretin hormone secreted by K-cells of the duodenum and proximal jejunum in response to dietary fat and carbohydrate ingestion.
GIP was originally named for its ability to inhibit gastric acid secretion (at supraphysiological concentrations), but its primary physiological role is as an incretin — it potentiates glucose-stimulated insulin secretion from pancreatic beta cells. Together with GLP-1, GIP accounts for approximately 50-70% of total postprandial insulin secretion.
GIP's receptor (GIPR) is expressed not only on pancreatic beta cells but also on adipocytes, osteoblasts, cardiomyocytes, neurons, and immune cells, making GIP a pleiotropic metabolic regulator.
The historical view of GIP in type 2 diabetes was that it was "diabetogenic" because GIP's insulinotropic effect is blunted (GIPR resistance) in obese and type 2 diabetic individuals, while its adipogenic effects are preserved. This made GIP an unattractive drug target — until the discovery that GIPR agonism in the setting of GLP-1R co-agonism (as in tirzepatide) produces greater weight loss than GLP-1R agonism alone.
The SURPASS-2 trial (Frias et al., NEJM 2021) demonstrated that tirzepatide at 15 mg produced 2.4% greater HbA1c reduction and approximately 5 kg greater weight loss vs semaglutide 1 mg weekly. This superiority is widely attributed to tirzepatide's GIP receptor agonism, though the exact mechanism — whether central (hypothalamic GIPRs reducing food intake) or peripheral (adipose GIPR effects on fat redistribution) — remains an active area of research.
GIP research continues to expand beyond metabolic disease into bone health (GIPR deletion in mice reduces bone formation), cardiac protection (GIPR agonism reduces ischemia-reperfusion injury in animal models), and neuroinflammation.
By the Numbers
Key Research Benefits
Documented effects observed in preclinical and clinical studies on GIP (Glucose-dependent Insulinotropic Polypeptide). See all Metabolic & Weight peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Endogenous GIP is studied as a research reference standard. In the context of drug research, GIPR agonism is studied through tirzepatide (GIP/GLP-1 dual agonist) or dedicated GIPR agonists in development.
For research purposes: IV/SC infusion at 1-4 pmol/kg/min for insulin secretion studies Context: GIP alone has minimal weight-loss effect in most human studies — its benefit in metabolic disease is synergistic with GLP-1R agonism Tirzepatide doses (clinically studied): 5 mg, 10 mg, 15 mg weekly SC
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Used as research peptide for mechanistic incretin studies. For translational research, tirzepatide (which contains a GIP-mimetic component) is the established dual-agonist framework.
What the research doesn't show
GIP's mechanism in tirzepatide's superior efficacy is not fully understood. Initially GIP was thought to be a minor player -- some evidence suggests GIP receptor activation in adipose tissue, some suggests central nervous system effects, some researchers believe GIP's contribution is primarily sensitizing the GLP-1 response. The debate is ongoing in academic pharmacology, and tirzepatide's 22% weight loss result may be working through mechanisms not yet fully characterized.
Medical Expert Videos
Physicians, researchers, and pharmacologists explain GIP (Glucose-dependent Insulinotropic Polypeptide), covering mechanisms of action, clinical context, and study findings.
Videos sourced from YouTube search. KnowYourPeptide does not endorse any individual creator. For research education only.
The Bottom Line
GIP (Glucose-dependent Insulinotropic Polypeptide) has a growing body of preclinical evidence and a well-characterised safety profile in research settings. The most-studied application is: potentiates glucose-dependent insulin secretion from pancreatic beta cells — a foundational incretin effect.
The most commonly reported side effect in research subjects is endogenous gip is involved in fat storage — historically considered 'diabetogenic' in type 2 diabetes. It is a research chemical, not approved for human use.
Frequently Asked Questions
Explore Further
Quick Reference
How It Compares
GLP-1 is GIP's incretin partner -- both are released postprandially, both stimulate insulin. Tirzepatide hits both receptors simultaneously and outperforms GLP-1 monotherapy significantly. Retatrutide is a triple agonist (GLP-1 + GIP + glucagon), which preliminary data suggests may be even more potent. The entire direction of obesity pharmacology has shifted from GLP-1 monotherapy toward combination receptor targeting based on GIP's unexpected contribution to tirzepatide's results.
Compare GIP (Glucose-dependent Insulinotropic Polypeptide) side-by-sideResearch Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.